Platelet-Rich Plasma and Cell Therapy
Bellus Medical, a leader in medical aesthetics, is excited to announce a new partnership with RegenLab, a leading innovator of medical products for the preparation of platelet-rich plasma and cell therapy. RegenLab is a Swiss-based biotechnology and medical device company that sells products in more than 80 countries, marketed under the world-famous REGENLAB® brand, including its RegenKit® products.
What this means for Bellus Medical – and you!
Bellus Medical is now the exclusive provider of the RegenLab A-CP family kits system, a simple, easy-to-use PRP technology indicated for use by the FDA for the safe and rapid preparation of autologous platelet-rich plasma from a small sample of blood for mixing with bone graft to improve handling characteristics. The system is scientifically validated with 510(k) clearance, providing practices the confidence in the quality of platelets available to use for various applications.
An Industry Need
The timing is perfect for this partnership as PRP has become one of the cutting-edge technologies for a number of medical applications including orthopedics. In fact, the global platelet-rich plasma (PRP) market size was valued at $214 million in 2016 and is expected to reach $647 million by 2025*.
As you know, Bellus Medical is a leader in medical aesthetics, committed to always providing the highest levels of safe and effective products, along with the most innovative technology on the market. That’s why we are proud to partner with RegenLab, an industry leader that shares this crucial commitment.
If you’re looking to optimize your PRP business, you’ll want this very simple, easy-to-use system. Together, we can help you grow your practice with the very best products and services.
*Grand View Research, Inc. report: Platelet Rich Plasma (PRP) Market Analysis By Application (Orthopedics, Cosmetic Surgery, Ophthalmic Surgery, Neurosurgery), And Segment Forecasts, 2014 – 2025
The RegenKit® BCT product family is indicated to be used for the safe and rapid preparation of autologous platelet-rich plasma (PRP) from a small sample of blood at the patient’s point of care. The PRP is mixed with autograft and/or allograft bone prior to application to an orthopedic surgical site as deemed necessary by the clinical use requirements.